IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Takeda an nounced it was con sid er ing mov ing pro duc tion of five an ti bi ot ics (lilacillin, melysin, amolin,
solcillin and vasicillin) to Meiji Seika’s In do ne sian sub sid iary, Meiji In do ne sian Phar ma ceu ti cal In dus tries,
due to the in tro duc tion of stricter GMP reg u la tions in Ja pan. These re quire sep a rate man u fac tur ing of
peni cil lins and cephalosporins. Takeda ap plied to im port the an ti bi ot ics into Ja pan. The move was also
part of Takeda’s re struc tur ing plan to improve costs and production.
Takeda set up Takeda UK to man age sales, in clud ing those of Amias (candesartan cilexetil), and Basen
(voglibose), and launch new prod ucts in de pend ently.
• Year: 1996
Takeda an nounced the com ple tion of a “Bio-Re search Build ing” at its Osaka plant. The Drug Safety Re -
search Lab o ra to ries in Takatsuki City will move into the new re search fa cil ity to strengthen ties with the
com pany’s Phar ma ceu ti cal Re search Di vi sion and in crease the ef fi ciency of R&D operations.
Takeda an nounced plans for a new man u fac tur ing fa cil ity at its Hikari site in Yamaguchi Pre fec ture to
man u fac ture a de pot for mu la tion of leuprorelin, and an in ject able form of lansoprazole.
Tianjin Pharmaceuticals Takeda Co, Takeda’s joint ven ture with Lisheng Phar ma ceu ti cal Fac tory Tianjin
(China), be gan op er a tions. 75%-owned by Takeda, it will man u fac ture Takeda drugs and carry out sales
pro mo tion and mar ket ing ac tiv i ties, with med i cal rep re sen ta tives op er at ing from sales of fices in Beijing,
Tianjin, Shanghai and Guangzhou.
• Year: 1995
Takeda Pharma GmbH (Ger many), a joint ven ture with Gruenenthal, es tab lished Takeda Pharma
GesmbH (Aus tria).
Takeda opened a new UK cen ter in Lon don. This was re spon si ble for con duct ing clin i cal tri als in the UK
and Ire land un der as sign ment from, and jointly with, the R&D Cen ter in Frank furt, Germany.
Takeda an nounced a cut in the work force of 32% as part of a re struc tur ing plan. The staff cuts will take
place grad u ally with staff num bers be ing re duced by about 3,500 to ap prox i mately 7,500 by 2005.
• Year: 1994
Takeda and Astra (now AstraZeneca, UK) reached an out-of-court set tle ment of all le gal ac tions re lat ing
to their pat ent dis pute con cern ing omeprazole and lansoprazole. Astra had al leged that Takeda’s
Takepron in fringed its pat ent for Losec. The two also an nounced plans to co-de velop Takeda’s Blopress
(candesartan cilexetil).
• Year: 1993
Takeda im ple mented a ma jor re or ga ni za tion of its three US sub sid iar ies. Takeda Chem i cal Prod ucts
(TCP) merged with Takeda USA and Takeda Fi nance to form Takeda America.
Takeda an nounced its with drawal from the food busi ness in Thai land when it sold its share in the joint
ven ture Better Home Foods.
• Year: 1992
Takeda set up a sales sub sid iary in Sin ga pore, Takeda Vi ta min and Food Asia Pte.
© 2009 IMS Health In cor po rated or its af fil i ates Page 120